Polypharmacy in Type 2 Diabetes Mellitus and Related Conditions: A Double-Edged Sword: A Narrative Review
Advances in Clinical Pharmacology and Therapeutics · 2025
DOI: 10.63623/sr9fb890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical Pharmacology and Therapeutics, 2025. Verfasst von Lutfullah Cakir. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus, Medikationssicherheit
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is a multifaceted metabolic disease that is often associated with comorbidities like cardiovascular disease, hypertension, and dyslipidemia. Managing these coexisting conditions often requires the concurrent use of multiple medications, leading to polypharmacy. Polypharmacy is defined as the use of five or more drugs by the patient. While polypharmacy can be clinically appropriate, it also raises the risk of adverse drug events, therapeutic duplication, poor adherence, and increased healthcare burden. Polypharmacy affects 50-80% of patients with T2DM, especially in older adults. It is associated with increased risks of hypoglycemia, hospitalization, drug–drug interactions, and decreased adherence to antidiabetic therapies. The presence of polypharmacy may compromise glycemic control and is linked to higher rates of diabetes-related complications and mortality. On the other hand, appropriate polypharmacy, based on guideline-directed care, can improve cardiovascular and renal outcomes when carefully managed. Polypharmacy in T2DM represents a clinical challenge that requires a balance between comprehensive disease management and the minimization of iatrogenic harm. Individualized care, regular medication reviews, and deprescribing strategies are essential to optimize therapeutic outcomes in this high-risk population. This review seeks to examine the prevalence, underlying causes, clinical consequences, and management approaches of polypharmacy in individuals with T2DM, with a focus on its impact on glycemic control, treatment safety, and associated outcomes.
Zitieren
APA
Cakir, L. (2025). Polypharmacy in Type 2 Diabetes Mellitus and Related Conditions: A Double-Edged Sword: A Narrative Review. Advances in Clinical Pharmacology and Therapeutics. https://doi.org/10.63623/sr9fb890
Vancouver
Cakir L. Polypharmacy in Type 2 Diabetes Mellitus and Related Conditions: A Double-Edged Sword: A Narrative Review. Advances in Clinical Pharmacology and Therapeutics. 2025. doi:10.63623/sr9fb890
BibTeX
@article{Cakir2025,
author = {Cakir, Lutfullah},
title = {Polypharmacy in Type 2 Diabetes Mellitus and Related Conditions: A Double-Edged Sword: A Narrative Review},
journal = {Advances in Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.63623/sr9fb890}
}
EUVIMED